L26/P-767 Efficacy of HMG with Testosterone Gel and Growth Hormone versus HMG-Only in POSEIDON Groups 3 and 4: A Retrospective Study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1094 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von P. Bhayana und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does adding testosterone gel and growth hormone to HMG improve clinical pregnancy and reduce cycle attrition in POSEIDON Groups 3 and 4? Summary answer Adjuvant therapy significantly increased CPR in POSEIDON Group 3 (78.9% vs 37.5%, P = 0.008) and showed a non-significant trend toward higher transferable embryo yield. What is known already Management of POSEIDON Group 3 and 4 patients is challenging due to low ovarian reserve. Transdermal testosterone may upregulate FSH receptors, while growth hormone (GH) may enhance oocyte mitochondrial function. Although individual adjuvants have been studied, limited data exist on combined protocols stratified by POSEIDON groups. In poor responders, cycle attrition—the failure to reach embryo transfer—remains the primary hurdle. Investigating combined adjuvant strategies is therefore essential to maximize transferable embryo yield and improve pregnancy potential in these difficult-to-treat populations. Study design, size, duration This retrospective study was conducted at a single Level 2 ART clinic (2021–2025). Eighty-seven controlled ovarian stimulation cycles were analyzed, comparing a standard HMG-only protocol (N = 51) against an adjuvant-intensified protocol (N = 36). Participants/materials, setting, methods Participants were POSEIDON Groups 3 (<35 years) and 4 (>35 years) with AMH <1.2 ng/ml. All received 450IU HMG daily. The adjuvant group received 12.5mg transdermal testosterone gel for one month prior to stimulation, plus 4IU GH daily from stimulation day 1 until trigger. Outcomes included mature oocyte (M2) yield, transferable embryos, attrition rates, and clinical pregnancy rate (CPR). Main results and the role of chance Baseline characteristics including age and AMH were comparable between the two groups. In the total Intention-To-Treat (ITT) population, the Clinical Pregnancy Rate (CPR) was 52.8% (19/36) in the adjuvant group versus 35.3% (18/51) in the HMG-only group (p = 0.126). Subgroup analysis revealed a statistically significant benefit for POSEIDON Group 3 (Age <35). In this cohort, the adjuvant protocol demonstrated superior outcomes across all clinical milestones: ITT CPR was 78.9% (15/19) vs 37.5% (12/32) (p = 0.008); CPR per oocyte retrieval was 88.2% vs 41.4% (p = 0.002); and CPR per embryo transfer reached 93.8% vs 54.5% (p = 0.012). The yield of transferable embryos in Group 3 trended higher with adjuvants (2.41 =/- 1.4 vs 1.83 =/-1.5, p = 0.177), and the “No Transfer” rate post-retrieval was reduced to 5.3% compared to 21.9% in the control (p = 0.23). In POSEIDON Group 4 (Age ≥35), outcomes were biologically constrained by age, with ITT CPR (23.5% vs 31.6%) and mean mature oocyte (M2) yield (6.00 +/- 2.7 vs 5.55 +/-2.4) remaining statistically similar between protocols Mean total HMG dose and stimulation duration were comparable, indicating that the improved success in Group 3 was mediated by the adjuvant effect rather than increased gonadotropin load. Limitations, reasons for caution The retrospective design, single-center setting, and small sample size limit causal inference. While Group 3 results reached statistical significance, other endpoints showed non-significant trends. Lack of live birth data further warrants cautious interpretation until validated by prospective randomized trials. Wider implications of the findings This protocol supports combined adjuvant use in younger poor responders (POSEIDON Group 3), reducing cycle attrition and improving CPR. The absence of benefit in Group 4 highlights age-related biological barriers. Findings provide a clinical rationale for prospective trials in younger patients with diminished reserve Trial registration number No
Zitieren
APA
Bhayana, P., & Khanijo, P. (2026). L26/P-767 Efficacy of HMG with Testosterone Gel and Growth Hormone versus HMG-Only in POSEIDON Groups 3 and 4: A Retrospective Study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1094
Vancouver
Bhayana P, Khanijo P. L26/P-767 Efficacy of HMG with Testosterone Gel and Growth Hormone versus HMG-Only in POSEIDON Groups 3 and 4: A Retrospective Study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1094
BibTeX
@article{Bhayana2026,
author = {Bhayana, P. and Khanijo, P.},
title = {L26/P-767 Efficacy of HMG with Testosterone Gel and Growth Hormone versus HMG-Only in POSEIDON Groups 3 and 4: A Retrospective Study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1094}
}
EUVIMED